Revolution Medicines reports RMC-9805 clinical data: 30% ORR in 2L+ PDAC at 1,200 mg/day

Revolution Medicines, Inc.

RMC-9805 monotherapy showed no Grade 4/5 TRAEs, no discontinuations; 3% dose reduction rate overall (179 patients).
For 2L+ PDAC patients (n=40) at 1,200 mg/day, ORR 30% (confirmed + pending), DCR 80%.
Most common any-grade TRAEs at 1,200 mg/day: nausea (27%), diarrhea (20%), vomiting (15%), rash (10%).
Median treatment duration 2.8 months across all doses; data cutoff September 2, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.